Search
Search Results
##search.searchResults.foundPlural##
-
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2552PDF: 820HTML: 14935Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 293 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
2035PDF: 597Suppl. Files: 280HTML: 158 -
-
EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT Sinopharm Vaccination in Iranian Patients with Hemoglobinopathies
1497PDF: 709HTML: 223 -
THE IMPACT OF HUMAN PLATELET ANTIGEN ALLELE ON ANTIPLATELET ANTIBODIES AND CRYOGLOBULINS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND HEPATITIS C VIRUS-ASSOCIATED IMMUNE THROMBOCYTOPENIA Human platelet antigen and immune thrombocytopenia
987PDF: 849Suppl. Files: 452HTML: 276 -
THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis
1354PDF: 1411PDF: 999HTML: 200 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2361PDF: 1571HTML: 607 -
-
COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
1070PDF: 482HTML: 8151 -
MODULATING EFFECT OF THE ?158 G? (C?T) XMN-1 POLYMORPHISM IN INDIAN SICKLE CELL PATIENTS
1486PDF: 879HTML: 1419Table: 188 -
VIRAL HEPATITIS A TO E IN SOUTH MEDITERRANEAN COUNTRIES
1222PDF: 645HTML: 7718 -
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SEVERE PEDIATRIC SICKLE CELL DISEASE: OUTCOME AND LONG-TERM COMPLICATIONS, SAUDI EXPERIENCE AT KING FAISAL SPECIALIST HOSPITAL, RIYADH, SAUDI ARABIA HCT in in Severe Pediatric Sickle Cell Disease
1142PDF: 912HTML: 341 -
THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.
2084PDF: 1251Html: 270 -
How I treat acute and persistent sickle cell pain
1888PDF: 1106HTML: 475 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
953PDF: 528HTML: 716 -
Acute Panmyelosis with Myelofibrosis - A Rare Subtype of Acute Myeloid Leukemia
2790PDF: 957HTML: 3116flowcytometric result of peripheral blood sample: 171 -
NURSING MANAGEMENT OF HAEMORRHAGIC CYSTITIS IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTRE ITALIAN SURVEY Nursing management of haemorrhagic cystitis
1827PDF: 1040HTML: 226 -
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy
2758PDF: 758HTML: 1258Blood Count trend before and during lenalidomide treatment: 168Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 184 -
High Prevalence of Antiphospholipid Antibodies in Children with Non-Transfusion Dependent Thalassemia and Possible Correlations with Microparticles Antiphospholipid Antibodies and Thalassemia in children
869PDF: 592HTML: 274 -
EXTREMELY OLD PATIENTS HOSPITALIZED IN INTERNAL MEDICINE: WHAT ABOUT THEIR ANEMIA? Anemia in the elderly
1527PDF: 496HTML: 222 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
2450PDF: 1143HTML: 11789 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
1904PDF: 1149HTML: 262 -
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1100PDF: 480HTML: 223 -
-
HISTORY OF ACUTE PROMYELOCYTIC LEUKEMIA: A TALE OF ENDLESS REVOLUTION
3104PDF: 1104HTML: 1743







